Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Angeles Wealth Management LLC

Angeles Wealth Management LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 19.9% during the first quarter, Holdings Channel.com reports. The fund owned 1,255 shares of the pharmaceutical company’s stock after acquiring an additional 208 shares during the quarter. Angeles Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $608,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of VRTX. Capital World Investors grew its stake in shares of Vertex Pharmaceuticals by 5.7% in the 4th quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company’s stock worth $11,406,667,000 after purchasing an additional 1,514,993 shares during the last quarter. Capital Research Global Investors boosted its holdings in Vertex Pharmaceuticals by 15.8% during the fourth quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company’s stock worth $4,199,713,000 after buying an additional 1,426,746 shares in the last quarter. Wellington Management Group LLP grew its position in Vertex Pharmaceuticals by 23.3% in the fourth quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company’s stock worth $2,382,407,000 after buying an additional 1,117,214 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Vertex Pharmaceuticals by 17.2% in the first quarter. Jennison Associates LLC now owns 5,062,442 shares of the pharmaceutical company’s stock valued at $2,454,373,000 after buying an additional 744,680 shares in the last quarter. Finally, Edgewood Management LLC lifted its position in shares of Vertex Pharmaceuticals by 91.2% during the 4th quarter. Edgewood Management LLC now owns 2,956,608 shares of the pharmaceutical company’s stock valued at $1,190,626,000 after acquiring an additional 1,410,238 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. The Goldman Sachs Group restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Royal Bank Of Canada set a $420.00 price target on Vertex Pharmaceuticals and gave the stock a “sector perform” rating in a research note on Tuesday, June 17th. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Bank of America raised their target price on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Finally, Wolfe Research lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a report on Wednesday, May 7th. Fourteen equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $512.30.

Vertex Pharmaceuticals Trading Down 0.6%

Shares of NASDAQ:VRTX opened at $469.65 on Friday. The company has a current ratio of 2.65, a quick ratio of 2.29 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $120.60 billion, a PE ratio of -119.81 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The firm has a fifty day moving average price of $453.13 and a 200 day moving average price of $464.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter last year, the company posted $4.76 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. Analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.